JBIO Jade Biosciences, Inc.
Price Chart
Executive Summary
Jade Biosciences filed a $600M universal shelf registration statement, including a $200M at-the-market (ATM) equity offering via Jefferies, concurrent with a Q1 2026 earnings miss (EPS -$0.57 vs -$0.52 consensus) and widened net loss. The ATM could dilute existing shareholders by up to ~16% at current prices, reinforcing a bearish outlook as the company burns cash with no near-term revenue prospects.
Key Financial Metrics
Actionable Insight
Expect ongoing selling pressure as the company likely draws on the ATM to fund operating losses. Monitor daily volume and market impact of ATM sales. Key catalyst: phase 1 data for JADE101 expected at ERA Congress, but dilution risk may cap upside.
Key Facts
- Filed S-3 shelf for up to $600M in securities, with $200M ATM component via Jefferies.
- Q1 2026 EPS -$0.57 vs consensus -$0.52; net loss widened to $40.4M from $38.2M YoY.
- Cash and investments declined to $311M from $336M as of Dec 2025.
- Proceeds from ATM to be used for working capital and general corporate purposes.
- At assumed price of $25.26/share, full $200M ATM would add ~7.9M shares, diluting existing holders by ~16%.
Financial Impact
Up to $200M in potential equity issuance, representing ~16% dilution at current market cap of $1.2B.
Risk Factors
- Significant dilution from potential ATM issuance.
- No approved products; pipeline setback could accelerate cash burn.
- Q1 earnings miss and widening losses increase urgency of capital raise.
- Market may perceive offering as a sign of financial weakness.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-212422 |
| Document: d132368dex45.htm | 0001193125-26-212422 |
| Document: d132368dex12.htm | 0001193125-26-212422 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
Press Release
| $16.91 awaiting T+1 | awaiting T+1 | — | $14.98 (+11.41%) |
|
Jun 4, 2026
5d ago
|
8-K
| $17.52 awaiting T+1 | awaiting T+1 | — | $14.98 (+14.50%) |
|
Jun 4, 2026
5d ago
|
424B5
| $17.52 awaiting T+1 | awaiting T+1 | — | $14.98 (+14.50%) |
|
Jun 4, 2026
6d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.91% | $14.98 (+15.56%) |
|
Jun 3, 2026
6d ago
|
424B5
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $14.98 (+15.56%) |
|
Jun 3, 2026
6d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $14.98 (+15.56%) |
|
Jun 1, 2026
8d ago
|
8-K
| $18.59 $17.75 | ▼ −4.52% | ▼ −4.66% | $14.98 (−19.42%) |
|
May 26, 2026
14d ago
|
Press Release
| $21.50 $20.84 | ▼ −3.07% | ▼ −3.62% | $14.98 (−30.33%) |
|
May 18, 2026
23d ago
|
EFFECT
| $22.01 $21.88 | ▲ +0.59% | ▼ −0.06% | $14.98 (+31.94%) |
|
May 7, 2026
4w ago
|
S-3
| $25.81 $24.86 | ▲ +3.68% | ▲ +3.91% | $14.98 (+41.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access